Literature DB >> 21494840

Role of RAAS Inhibition in the Prevention of Cardiovascular Disease.

Henry A Tran1, Arthur Schwartzbard, Howard S Weintraub.   

Abstract

OPINION STATEMENT: The pathogenesis of cardiovascular disease is a complex and dynamic process. The renin-angiotensin-aldosterone system (RAAS) is a potent and powerful mediator in the homeostasis of the cardiovascular and renal systems. RAAS blockade via angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) has been consistently proven to be an effective and safe strategy for the primary and secondary prevention of cardiovascular disease in patients across a wide spectrum of risk. Although the beneficial effects of RAAS blockade may be due to its effects on central and peripheral blood pressure, there are many additional mechanisms to consider that may contribute additional protection. While a combination of ACE inhibitors and ARBs has not yielded significantly positive results, the newer class of direct renin inhibitors (DRIs) may offer a novel and effective strategy for monotherapy as well as in combination.

Entities:  

Year:  2011        PMID: 21494840     DOI: 10.1007/s11936-011-0126-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  28 in total

Review 1.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.

Authors:  Ilke Sipahi; Sara M Debanne; Douglas Y Rowland; Daniel I Simon; James C Fang
Journal:  Lancet Oncol       Date:  2010-06-11       Impact factor: 41.316

2.  Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.

Authors:  Sripal Bangalore; Sunil Kumar; Sverre E Kjeldsen; Harikrishna Makani; Ehud Grossman; Jørn Wetterslev; Ajay K Gupta; Peter S Sever; Christian Gluud; Franz H Messerli
Journal:  Lancet Oncol       Date:  2010-11-29       Impact factor: 41.316

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 4.  Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.

Authors:  Daniel A Duprez
Journal:  J Hypertens       Date:  2006-06       Impact factor: 4.844

5.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Mathieu Ghadanfar; Nicole Weissbach; Zhihua Xiang; Juergen Armbrecht; Marc A Pfeffer
Journal:  Nephrol Dial Transplant       Date:  2009-01-14       Impact factor: 5.992

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

10.  Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians.

Authors:  Vincenza Snow; Patricia Barry; Stephan D Fihn; Raymond J Gibbons; Douglas K Owens; Sankey V Williams; Christel Mottur-Pilson; Kevin B Weiss
Journal:  Ann Intern Med       Date:  2004-10-05       Impact factor: 25.391

View more
  2 in total

1.  Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta.

Authors:  Mojca Lunder; Lovro Ziberna; Miodrag Janić; Aleš Jerin; Milan Skitek; Mišo Sabovič; Gorazd Drevenšek
Journal:  Heart Vessels       Date:  2012-05-21       Impact factor: 2.037

2.  Angiogenesis in mesenteric microvascular networks from spontaneously hypertensive versus normotensive rats.

Authors:  Ming Yang; Mario Aragon; Walter L Murfee
Journal:  Microcirculation       Date:  2011-10       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.